Ovid Therapeutics (OVID) Net Income towards Common Stockholders (2016 - 2026)
Ovid Therapeutics (OVID) posted Net Income towards Common Stockholders of -$17.0 million for Q1 2026, down 275.8% on a QoQ basis from $9.7 million in Q4 2025, and down 65.98% year-over-year from -$49.9 million in Q1 2025.
Ovid Therapeutics (OVID) Net Income towards Common Stockholders (2016 - 2026) Analysis & Trends
Ovid Therapeutics' Net Income towards Common Stockholders history runs 11 years deep, the most recent figure standing at -$17.0 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 65.98% year-over-year to -$17.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24.2 million (up 3.23% YoY) and the FY2025 annual result came in at -$17.4 million, up 34.12% from the prior year.
- Net Income towards Common Stockholders was -$17.0 million for Q1 2026 at Ovid Therapeutics, down from $9.7 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $9.7 million in Q4 2025 and bottomed at -$17.0 million in Q1 2026.
- A 5-year average of -$9.8 million and a median of -$12.0 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Peak annual rise in Net Income towards Common Stockholders reached 204.43% in 2025, while the deepest fall reached 154.97% in 2025.
- Ovid Therapeutics' Net Income towards Common Stockholders stood at -$11.5 million in 2022, then tumbled by 33.18% to -$15.3 million in 2023, then surged by 39.61% to -$9.3 million in 2024, then surged by 204.43% to $9.7 million in 2025, then plunged by 275.8% to -$17.0 million in 2026.
- Business Quant data shows OVID's Net Income towards Common Stockholders at -$17.0 million in Q1 2026, $9.7 million in Q4 2025, and -$12.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Ovid Therapeutics | 118.66 Mn | -36.86 Mn | - | -16.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.99 Mn |
| Dec 31, 2025 | 9.66 Mn |
| Sep 30, 2025 | -12.16 Mn |
| Jun 30, 2025 | -4.68 Mn |
| Mar 31, 2025 | -10.24 Mn |
| Dec 31, 2024 | -9.25 Mn |
| Sep 30, 2024 | -14.01 Mn |
| Jun 30, 2024 | 8.52 Mn |
| Mar 31, 2024 | -11.69 Mn |
| Dec 31, 2023 | -15.32 Mn |
| Sep 30, 2023 | -11.25 Mn |
| Jun 30, 2023 | -12.41 Mn |
| Mar 31, 2023 | -13.36 Mn |
| Dec 31, 2022 | -11.50 Mn |
| Sep 30, 2022 | -11.97 Mn |
| Jun 30, 2022 | -14.59 Mn |
| Mar 31, 2022 | -16.11 Mn |
| Dec 31, 2021 | -26.00 Mn |
| Sep 30, 2021 | -11.38 Mn |
| Jun 30, 2021 | -15.79 Mn |